Soligenix Inc.

SNGX Healthcare Biotechnology

Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023. In the quarter to June 2026, EPS grew 85.4% and free cash flow grew 37.8%, each against the same quarter a year earlier.

0.35 0.01 −2.78%
Market cap
$7.7M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
n/a
Altman Z
−38.90
Beneish M
n/a
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Piotroski F-Score
3 3 2 2 2 4 4 3 — —
Altman Z-Score
(18.80) (21.80) (22.21) (32.63) (14.45) (10.41) (24.28) (33.86) (38.90) —
P/S ratio
0.79 2.53 2.16 6.07 14.92 32.13 21.78 7.86 9.06 —
Altman Z″-Score (non-manufacturers)
(44.07) (52.73) (52.04) (81.46) (33.29) (22.59) (58.20) (77.77) (88.34) —
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
P/Operating CF
(5.79) (5.94) (4.23) (10.64) (8.53) (8.67) (5.70) (3.61) (2.01) —
Beneish M-Score
(1.84) (2.46) (2.93) (3.34) (5.21) (3.00) (2.93) 0.17 — —
P/B ratio
1.12 2.18 1.80 19.30 9.41 2.47 0.00 2.62 1.09 —
Price to Tangible BV
1.13 2.20 1.82 19.56 9.42 2.47 0.00 2.62 1.09 —
EV/Sales
(0.05) 1.10 0.45 4.93 11.36 12.62 18.38 1.68 (1.93) —
EV/EBITDA
0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 —
EV/Operating CF
0.11 (0.91) (0.32) (3.04) (2.34) (0.89) (1.38) (0.16) 0.11 —
EV/FCF
0.11 (0.91) (0.32) (3.03) (2.34) (0.89) (1.38) (0.16) 0.11 —
Quick Ratio
3.48 2.83 2.42 1.09 3.16 4.18 0.82 1.40 1.61 2.15
Current Ratio
3.52 2.92 2.46 1.19 3.20 4.22 0.84 1.55 1.82 2.39
Net Debt/EBITDA
1.56 1.04 1.00 0.50 0.45 1.23 0.23 0.68 0.68 0.67
Debt/Assets
0.00% 0.00% 0.00% 1.64% 51.67% 37.08% 70.95% 33.28% 15.31% 0.00%
Debt/Equity
0.00 0.00 0.00 0.09 2.75 0.93 (4.10) 1.29 0.33 0.00
Asset Turnover
1.18 0.55 0.52 0.51 0.17 0.04 0.05 0.07 0.01 0.00
Operating CF/Net income
1.54 0.91 0.81 0.80 0.65 0.94 0.92 1.40 1.02 0.93
Capex/Depreciation
(0.07) (0.38) (0.02) (0.45) (0.11) (0.16) (0.20) 0.00 0.00 (1.84)
Interest Coverage
(2,595.27) — (56.97) (70.74) (1,705.18) (14.48) (17.31) (156.78) 44.11 —
ROE
(87.96%) (104.21%) (141.27%) (241.83%) (680.47%) (173.54%) (334.43%) (23,801.16%) (248.98%) (235.50%)
ROA
(36.77%) (72.13%) (88.82%) (102.43%) (127.87%) (53.68%) (67.06%) (51.01%) (88.11%) (121.75%)
ROIC
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(44.64%) (114.85%) (144.70%) (768.55%) (131.91%) (61.83%) 521.64% (182.37%) (207.38%) (214.80%)
Average Days of Receivables
42.16 90.24 83.68 115.33 87.39 107.47 84.36 84.84 0.00 —
Research and Development Expense of Revenue
41.11% 101.37% 128.80% 175.44% 627.12% 993.07% 837.19% 394.65% 4,374.87% 0.00%
Selling, General and Administrative Expense of Revenue
32.82% 59.07% 56.32% 75.18% 183.47% 607.63% 705.33% 534.02% 3,530.90% 0.00%
Intangible Assets out of Total Assets
0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
6.01% 9.12% 7.27% 8.13% 17.37% 47.20% 57.48% 58.76% 289.45% 0.00%
Graham Net Nets
0.88 0.45 0.54 0.04 0.09 0.39 (0.14) 0.34 0.89 —
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 155.86 0.00 0.00 —
Earnings Yield
(40.03%) (52.05%) (86.00%) (33.78%) (52.32%) (46.95%) (68.05%) (105.88%) (226.30%) —
Free Cash Flow Yield
(60.50%) (47.50%) (63.94%) (26.79%) (32.56%) (44.37%) (61.27%) (130.64%) (187.79%) —
Revenue per Share
720.61 212.21 95.47 57.30 20.59 4.93 5.29 1.73 0.07 0.00
Operating CF per Share
(343.61) (254.32) (131.96) (92.94) (99.95) (70.21) (70.51) (17.74) (5.06) (1.98)
Capex per Share
(0.50) (1.03) (0.02) (0.31) (0.06) (0.07) (0.07) 0.00 0.00 0.00
Free Cash Flow per Share
(344.11) (255.35) (131.98) (93.25) (100.01) (70.28) (70.58) (17.74) (5.06) (1.98)
Cash per Share
605.01 305.06 163.64 67.09 162.97 155.77 74.47 17.41 4.71 1.53
Shareholders Equity per Share
510.15 246.86 114.39 18.03 32.65 64.13 (13.77) 5.20 2.48 1.02
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
510.15 246.86 114.39 18.03 32.65 64.13 (13.77) 5.20 2.48 1.02
Free Cash Flow
(4.99) (6.54) (7.25) (7.53) (11.46) (11.75) (12.66) (8.60) (8.40) (10.27)
Working Capital
7.24 6.19 6.13 1.18 13.39 20.28 (2.66) 3.36 3.98 5.15
Capital Expenditures
(0.01) (0.03) 0.00 (0.02) (0.01) (0.01) (0.01) — — (0.01)
Net Current Asset Value
7.24 6.19 6.13 1.18 3.32 10.42 (2.90) 2.23 3.98 4.91
EV/EBIT
0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 —
Capex to Sales
0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.00 0.00
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Other line items
Depreciation/Fixed assets
3.64 1.84 2.25 1.51 2.71 3.43 3.57 1.61 0.95 0.36
Cash ROIC
(30.86%) (46.27%) (47.47%) (107.56%) (35.05%) (25.15%) (60.24%) (60.47%) (63.14%) (77.66%)
Accounts Receivable Turnover
6.55 4.26 4.12 3.48 2.33 2.04 4.11 4.05 0.00 —
Accounts Payable Turnover
3.68 2.49 2.37 1.47 0.75 0.29 0.16 0.30 0.13 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Average Days of Payables
73.92 148.50 168.79 279.87 426.92 1,465.56 2,561.76 546.61 2,041.74 0.00
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Average Receivables
1.60 1.27 1.27 1.33 1.01 0.40 0.23 0.21 — —
Average Payables
2.29 1.73 1.94 2.43 2.43 2.53 3.40 2.49 0.89 0.89
Average Assets
8.83 9.91 10.02 9.13 13.83 23.38 20.57 12.04 9.38 9.10
Average Common Equity
3.69 6.86 6.30 3.87 2.60 7.23 4.13 0.03 3.32 4.71

Fold the line items

Columns are period end dates